Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine PCIA after pancreaticoduodenectomy in an ERAS pathway
ChiCTR1900026640Phase 4Not yet recruiting
- Sponsor
- Lanzhou University
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nalbuphine, sufentanil and ondansetron in postoperative pain (3 arms), sponsored by Lanzhou University. Primary endpoints: Heart rate, Noninvasive blood pressure and 10 more. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
nalbuphinesufentanilondansetron
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR1900026640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026640.